نتایج جستجو برای: jak2 mutation

تعداد نتایج: 294733  

Journal: :American journal of clinical pathology 2007
Angela Y C Tan David A Westerman Alexander Dobrovic

The point mutation 1849 (GT) V617F in the JAK2 gene occurs at high frequency in several chronic myeloproliferative diseases. Although a number of V617F mutation detection methods have been described, few are readily implemented in a diagnostic setting. We developed a simple and sensitive allelespecific competitive blocker polymerase chain reaction (ACB-PCR) assay to detect the V617F mutation. D...

2014
Claudia Carranza Damaris Tinti Luisa Rosales Mauricio Villegas

The Myeloproliferative Neoplasms (MPN) are classified as four major diseases: Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET) [1]. The translocation t(9;22)(q34;q11) produces the Philadelphia chromosome and causes the BCR-ABL1 transcript; this alteration is commonly found in CML [1]. In 2008 the World Health Organization (WH...

Journal: :Blood 2005
David P Steensma Gordon W Dewald Terra L Lasho Heather L Powell Rebecca F McClure Ross L Levine D Gary Gilliland Ayalew Tefferi

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow-derived genomic DNA from 245 pat...

Journal: :Haematologica 2016
Alberto Alvarez-Larrán Arturo Pereira Paola Guglielmelli Juan Carlos Hernández-Boluda Eduardo Arellano-Rodrigo Francisca Ferrer-Marín Alimam Samah Martin Griesshammer Ana Kerguelen Bjorn Andreasson Carmen Burgaleta Jiri Schwarz Valentín García-Gutiérrez Rosa Ayala Pere Barba María Teresa Gómez-Casares Chiara Paoli Beatrice Drexler Sonja Zweegman Mary F McMullin Jan Samuelsson Claire Harrison Francisco Cervantes Alessandro M Vannucchi Carlos Besses

The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up ...

2017
Kazuya Shimoda Kotaro Shide Takuro Kameda

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are categorized as myeloproliferative neoplasms (MPNs). All are characterized by the autonomous growth of one or more lineages of hematopoietic cells, splenomegaly, constitutional symptoms such as fatigue, night sweating, itching, and weight loss, and is frequently complicated by thrombosis and hemorrhage. J...

Journal: :Blood 2009
Lyndal Kearney David Gonzalez De Castro Jenny Yeung Julia Procter Sharon W Horsley Minenori Eguchi-Ishimae Caroline M Bateman Kristina Anderson Tracy Chaplin Bryan D Young Christine J Harrison Helena Kempski Chi Wai E So Anthony M Ford Mel Greaves

Children with Down syndrome (DS) have a greatly increased risk of acute megakaryoblastic leukemia (AMKL) and acute lymphoblastic leukemia (ALL). Both DS-AMKL and the related transient myeloproliferative disorder (TMD) have GATA1 mutations as obligatory, early events. To identify mutations contributing to leukemogenesis in DS-ALL, we undertook sequencing of candidate genes, including FLT3, RAS, ...

Journal: :Blood 2007
Luciana Teofili Fiorina Giona Maurizio Martini Tonia Cenci Francesco Guidi Lorenza Torti Giovanna Palumbo Angela Amendola Giuseppe Leone Robin Foà Luigi M Larocca

In the proposed revised World Health Organization (WHO) criteria for the diagnosis of BCR-ABL(-) myeloproliferative diseases (MPDs), exclusion criteria have been replaced by the presence of JAK2 mutations. We applied these criteria to 45 children with MPDs: 13 with polycythemia vera (PV) and 32 with essential thrombocythemia (ET). Among these 45 patients, 12 with ET and 5 with PV had a familial...

Journal: :African health sciences 2014
Musa Waiswa Emmanuel Seremba Ponsiana Ocama Henry Ddungu Keneth Opio Clement Okello Timothy O'shea Madeleine Verhovsek Richard Mutyabule

INTRODUCTION Splanchnic venous thrombosis (SVT) has varied etiology with Philadelphia-negative myeloproliferative neoplasms (MPNs) being the most frequent underlying prothrombotic factor. Hematological indices often remain within normal range because of portal hypertension and its sequelae, causing diagnostic challenges. The high frequency of JAK2 mutation among patients with SVT reinforces the...

Journal: :Blood 2017
Elisa Rumi Mario Cazzola

Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues includes new criteria for the diagnosis of these disorders. Somatic mutations in the 3 driver genes, that is, JAK2, CALR, and MPL, represe...

Journal: :The American journal of pathology 2014
Zan Huang Hai-Bin Ruan Zeng-Di Zhang Weiqian Chen Zhaoyu Lin Hu Zeng Xiang Gao

Myeloproliferative neoplasms constitute a group of hematopoietic neoplasms at the myeloid stem cell level. Although mutations in the receptor tyrosine kinase KIT have been identified in patients with myeloproliferative neoplasm, the functional causality is unknown because of a lack of animal models. Here, we describe a mouse strain harboring a point mutation in the first Ig-like domain of Kit. ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید